Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The outcome of high-dose chemotherapy (HDT) was evaluated retrospectively in 27 patients with myeloma and four patients with AL amyloidosis with severe renal impairment. Twenty-three patients were receiving dialysis and the rest had a creatinine clearance of <20 ml/min. The median melphalan dose was 140 mg/m2 (range: 60-200 mg/m2), but 10 patients (37%) received 200 mg/m2. Myeloid and platelet engraftment were similar to that seen in patients without renal failure. Five of 27 patients died of transplant-related toxicity before the day 100. Twenty of 27 patients had a response (70%). The median time to disease progression was 32 months (range: 6-54 months) and the median time to best response was 6.5 months. Four of 17 evaluable patients (24%) became dialysis-independent at a median of 5 months post-HDT/stem cell transplantation. At a median follow-up of 70 months, 7/23 patients with myeloma were alive but three of these seven patients had progressive disease. Two of the four patients with amyloidosis have survived. HDT is feasible in these patients and results in 5-year survival in about one-third of patients.

Original publication

DOI

10.1111/j.1365-2141.2006.06191.x

Type

Journal article

Journal

Br J Haematol

Publication Date

08/2006

Volume

134

Pages

385 - 390

Keywords

Adult, Aged, Amyloidosis, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Disease Progression, Drug Administration Schedule, Humans, Kidney Diseases, Middle Aged, Multiple Myeloma, Proportional Hazards Models, Renal Dialysis, Retrospective Studies, Statistics, Nonparametric, Stem Cell Transplantation, Survival Rate, Transplantation, Autologous, Treatment Outcome